21 research outputs found
Observation of narrow baryon resonance decaying into in pA-interactions at with SVD-2 setup
SVD-2 experiment data have been analyzed to search for an exotic baryon
state, the -baryon, in a decay mode at on IHEP
accelerator. The reaction with a limited multiplicity was
used in the analysis. The invariant mass spectrum shows a resonant
structure with and . The statistical significance of this peak was estimated to be of . The mass and width of the resonance is compatible with the recently
reported - baryon with positive strangeness which was predicted as an
exotic pentaquark () baryon state. The total cross section for
production in pN-interactions for was estimated to be
and no essential deviation from A-dependence for inelastic
events was found.Comment: 8 pages, 7 figures, To be submitted to Yadernaya Fizika. v3-v5 - Some
references added, minor typos correcte
Precision Measurement of the p(e,e ' p)pi(0) Reaction at Threshold
New results are reported from a measurement of electroproduction near
threshold using the reaction. The experiment was
designed to determine precisely the energy dependence of and wave
electromagnetic multipoles as a stringent test of the predictions of Chiral
Perturbation Theory (ChPT). The data were taken with an electron beam energy of
1192 MeV using a two-spectrometer setup in Hall A at Jefferson Lab. For the
first time, complete coverage of the and angles
in the center-of-mass was obtained for invariant energies above
threshold from 0.5 MeV up to 15 MeV. The 4-momentum transfer coverage
ranges from 0.05 to 0.155 (GeV/c) in fine steps. A simple phenomenological
analysis of our data shows strong disagreement with wave predictions from
ChPT for (GeV/c), while the wave predictions are in
reasonable agreement.Comment: 5 pages, 6 figure
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
Background
Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting) is an ongoing international, prospective registry of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) and at least one investigator-determined risk factor for stroke who received rivaroxaban as an initial treatment for the prevention of thromboembolic stroke. The aim of this paper is to describe the design of the RIVER registry and baseline characteristics of patients with newly diagnosed NVAF who received rivaroxaban as an initial treatment.
Methods and results
Between January 2014 and June 2017, RIVER investigators recruited 5072 patients at 309 centres in 17 countries. The aim was to enroll consecutive patients at sites where rivaroxaban was already routinely prescribed for stroke prevention. Each patient is being followed up prospectively for a minimum of 2-years. The registry will capture data on the rate and nature of all thromboembolic events (stroke / systemic embolism), bleeding complications, all-cause mortality and other major cardiovascular events as they occur. Data quality is assured through a combination of remote electronic monitoring and onsite monitoring (including source data verification in 10% of cases). Patients were mostly enrolled by cardiologists (n = 3776, 74.6%), by internal medicine specialists 14.2% (n = 718) and by primary care/general practice physicians 8.2% (n = 417). The mean (SD) age of the population was 69.5 (11.0) years, 44.3% were women. Mean (SD) CHADS2 score was 1.9 (1.2) and CHA2DS2-VASc scores was 3.2 (1.6). Almost all patients (98.5%) were prescribed with once daily dose of rivaroxaban, most commonly 20 mg (76.5%) and 15 mg (20.0%) as their initial treatment; 17.9% of patients received concomitant antiplatelet therapy. Most patients enrolled in RIVER met the recommended threshold for AC therapy (86.6% for 2012 ESC Guidelines, and 79.8% of patients according to 2016 ESC Guidelines).
Conclusions
The RIVER prospective registry will expand our knowledge of how rivaroxaban is prescribed in everyday practice and whether evidence from clinical trials can be translated to the broader cross-section of patients in the real world